Kintegral Advisory LLC Sells 192 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Kintegral Advisory LLC reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,128 shares of the medical instruments supplier’s stock after selling 192 shares during the period. Kintegral Advisory LLC’s holdings in West Pharmaceutical Services were worth $1,352,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in West Pharmaceutical Services during the fourth quarter valued at about $34,000. Centricity Wealth Management LLC acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $35,000. Cornerstone Planning Group LLC boosted its stake in West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 40 shares during the period. Brooklyn Investment Group acquired a new stake in West Pharmaceutical Services in the 3rd quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its position in West Pharmaceutical Services by 60.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 209 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 79 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Up 3.5 %

Shares of WST opened at $210.72 on Friday. The firm has a market capitalization of $15.24 billion, a PE ratio of 31.50, a price-to-earnings-growth ratio of 6.74 and a beta of 1.01. The stock’s fifty day simple moving average is $316.29 and its 200-day simple moving average is $310.62. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services, Inc. has a 12-month low of $197.01 and a 12-month high of $400.88.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07. The business had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be given a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 annualized dividend and a dividend yield of 0.40%. West Pharmaceutical Services’s dividend payout ratio is presently 12.56%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Bank of America increased their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. KeyCorp decreased their price target on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Citigroup started coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They issued a “buy” rating and a $400.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $344.00.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.